Off-Label Prescriptions in Dermatology: Challenges of New Routes of Administration for Certain Old Drugs

被引:1
|
作者
Tasic-Kostov, Marija [1 ]
Ilic, Dusan [1 ]
机构
[1] Univ Nis, Fac Med, Dept Pharm, Nish, Serbia
关键词
off-label drug; dermatology; compounded drugs; drug vehicle; INFANTILE HEMANGIOMAS; TOPICAL PROPRANOLOL; SPIRONOLACTONE; THERAPY; SAFETY; ACNE; GEL;
D O I
10.5937/afmnai37-25282
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
"Off-label drug use" refers to the prescription of medications, with reference to indications, dosage, dosage form, patient group or route of administration, which are officially unapproved. Recently, new indications for some drugs have emerged and few of them are being used off-label to treat topically a variety of dermatological conditions. Off-label use is more common in dermatology than in other medical specialties, and those drugs are basically available as compounded formulations, but the choice of a proper vehicle and safety of extemporaneous drug preparation intended for topical use are usually neglected in case of systemic drugs. Moreover, the bases commonly used as vehicles for extemporaneous dermatological preparations are stabilized with traditional surfactants known for their potential to irritate skin, while inflammatory dermatoses can worsen when exposed to irritants In this paper, we have listed several systemic drugs which are being used in topical treatment of some frequent dermatological conditions, but not according to their officially approved indications. The choice of drugs was made according to the topical off-label dermatological prescriptions obtained from public pharmacies. The aim was also to review data related to, in our opinion, two major drawbacks of using off-label topical drugs: safety data on the use of the final dermal preparation and scientific information relevant for the choice of a proper topical vehicle for specific drug and proper stability evaluation.
引用
收藏
页码:131 / 138
页数:8
相关论文
共 50 条
  • [21] Off-label prescriptions: patient safety first
    不详
    LANCET ONCOLOGY, 2011, 12 (09): : 825 - 825
  • [22] Retapamulin Prescriptions and Monitored Off-Label Use
    Linda M. Mundy
    Tim Sampson
    John W. Logie
    Pediatric Drugs, 2014, 16 : 331 - 336
  • [23] Off-label prescriptions for atopic dermatitis in Europe
    Bieber, T.
    Straeter, B.
    ALLERGY, 2015, 70 (01) : 6 - 11
  • [24] The professional liability of clinicians for off-label prescriptions
    Zagari, A.
    ITALIAN JOURNAL OF MEDICINE, 2007, 1 (03) : 76 - 79
  • [25] Off-label prescriptions of quetiapine for sleep disturbances
    Arts, M.
    Petrykiv, S.
    Fennema, J.
    De Jonge, L.
    EUROPEAN PSYCHIATRY, 2017, 41 : S749 - S750
  • [26] Retapamulin Prescriptions and Monitored Off-Label Use
    Mundy, Linda M.
    Sampson, Tim
    Logie, John W.
    PEDIATRIC DRUGS, 2014, 16 (04) : 331 - 336
  • [27] The use of "off-label"' drugs
    Broadman, LM
    Semenov, I
    ANESTHESIA AND ANALGESIA, 2006, 103 (01): : 250 - 251
  • [28] Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis
    Simsek, Melek
    Lissenberg-Witte, Birgit I.
    van Riswijk, Milou L. M.
    Verschuren, Sander
    Hoentjen, Frank
    Oldenburg, Bas
    Ponsioen, Cyriel Y.
    van der Woude, C. Janneke
    van der Meulen, Andrea E.
    Pierik, Marieke
    Dijkstra, Gerard
    de Boer, Nanne K. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (10) : 1293 - 1300
  • [29] Off-label Studies on the Use of Ruxolitinib in Dermatology
    Tegtmeyer, Kyle
    Ravi, Mohan
    Zhao, Jeffrey
    Maloney, Nolan J.
    Lio, Peter A.
    DERMATITIS, 2021, 32 (03) : 164 - 172
  • [30] Off-Label Uses of JAK Inhibitors in Dermatology
    Nussbaum, Dillon
    McCormick, Erika
    Desai, Sapana
    Murphy, Emily
    Saardi, Karl
    Friedman, Adam
    JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (10) : 1143 - 1146